Predicting Chemoresistance in HER2-low Breast Cancer: Histologic Grade, MRI Non-mass Enhancement, and Clinical T Stage
Background/Aim: Human epidermal growth factor receptor 2 (HER2)-low breast cancer shows consistently low pathological complete response (pCR) rates after neoadjuvant chemotherapy (NAC), yet no preoperative tool exists to identify non-responders for whom alternative strategies – including upfront surgery or early trastu...